gv101
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 10, 2021 (NCT05068947)
Timeline
Indications
Studied for
Mechanism of action
- Rho-associated protein kinase 2INHIBITOR
ROCK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06979505 | Phase 2 | Jun 30, 2025 | Graviton Bioscience Corporation |
| NCT05068947 | Phase 1 | Sep 10, 2021 | Graviton Bioscience Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Graviton Bioscience Corporation | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1